Asia Beat: Taiwan jostles for position in Asian biotech battle
This article was originally published in Scrip
Recent developments in South Korea's biotech sector have set off alarm bells in Taiwan, where some leading researchers are warning that the island's nascent industry risks being left behind in a field the government has already designated as economically important.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.